Bloomberg BNA Publishes Akin Gump Article on Emerging Trends in Biopharma IPR and PGR Proceedings

Bloomberg BNA’s Patent, Trademark & Copyright Journal has published the article “Emerging Trends in Biopharma IPR and PGR Proceedings,” written by Akin Gump partner Rubén Muñoz, counsel Melissa Gibson and associate Jonathan Underwood, all members of the firm’s intellectual property practice.

The article analyzes trends in the institution and final decisions of inter partes review (IPR) proceedings in the biological and pharmaceutical arts. The authors note that, since the enactment of the America Invests Act in 2011, IPR and post-grant review (PGR) proceedings have emerged as particularly relevant for challenging biopharma patents before the U.S. Patent and Trademark Office. Most notably, they write, “biopharma IPR petitions [are] instituted less frequently than all other petitions, and [] the chance that the instituted claims will survive the final written decision is greater for biopharma IPR petitions than for all other petitions.”

To learn more about new trends in biopharma IPR and PGR proceedings, please click here to read the full article.